The remaining $800 million of the settlement payment resolves Lilly's civil liability under the False Claims Act and related state claims. The qui tam relators, all of whom are former Lilly sales representatives, will share in $78.8 million, which represents 18% of the federal government's civil share. State Medicaid programs can opt into the settlement and share in up to $361.8 million. You may recall that Alaska settled with Lilly in March of last year for $15 million. It was reported that Alaska was motivated to settle, at least in part, based upon concerns that a Supreme Court decision in Wyeth v. Levine would undercut its (and others) suits.. As is typical in connection with these settlements, Lilly also entered into a Corporate Integrity Agreement with the HHS OIG, which agreed to refrain from exercising its permissive exclusion authority.